Quantcast

Latest treatment of multiple sclerosis Stories

2014-09-04 04:21:59

~Crew of Sailors with MS including Bostonian Demonstrate Ability to Overcome Personal Challenges BOSTON, Sept. 4, 2014 /PRNewswire/ -- On Thursday, September 11th at 8:30 a.m., MSBoston2014 -- the world's largest international conference exclusively devoted to research in multiple sclerosis (MS) -- will host its opening ceremony with Dr. Dhib-Jalbut, President of ACTRIMS, providing an overarching look at the MS landscape. In his address, he will underscore the critical importance of MS...

2014-08-29 08:24:31

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous...

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-06-25 12:30:05

MISSISSAUGA, ON, June 25, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERA(TM) is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA(TM) is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1) "TECFIDERA is...

2014-06-12 12:30:07

Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for...

2014-05-27 08:28:11

NESS ZIONA, Israel, May 27, 2014 /PRNewswire/ -- Mapi Pharma Ltd. ("Mapi" or the "Company"), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company's Glatiramer Acetate Depot has been extended until December 2030. The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to...

2014-05-27 08:27:32

MISSISSAUGA, ON, May 27, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in Ontario through the Ontario Public Drugs Program's (OPDP) Exceptional Access Program (EAP), as indicated in the upcoming May 29, 2014, Edition No. 42, Ontario Drug Benefit Formulary/Comparative Index. TECFIDERA(TM) is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA(TM) is indicated as...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-15 23:02:24

Crowdfunding Gets FDA-Approved Stem Cell Trial Off To Fast Start New York, NY (PRWEB) April 15, 2014 The Tisch MS Research Center of New York (Tisch MSRCNY) today announced that they surpassed their campaign goal on Indiegogo.com to raise funds for their FDA-Approved Phase I Clinical Stem Cell Trial. The funding will be directly applied to the study and stem cell research at Tisch MSRCNY. The target of $300K was met and surpassed within the allotted four weeks of the campaign's launch...

2014-04-11 16:21:36

DUBLIN, April 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market Report" [http://www.researchandmarkets.com/research/btp9ds/global_multiple ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related